Today results of our picks
RIL
KOPRAN
MANGALAM ORGANIC
HDFC LIFE
GLAND PHARMA
RIL
KOPRAN
MANGALAM ORGANIC
HDFC LIFE
GLAND PHARMA
Wealthcreatures.com
CYIENT CMP - 379 BOOK VALUE - 232 DIVIDEND YIELD - 3.9% Accmulation- 350 TO 379 ZONE Support - 335 COMPANY CAN POST RS.35 TO 37 EPS FOR FY21. IN NEXT 1 TO 2 QTR STOCK CAN TEST ITS 52wk HIGH OF 513 Won't be suprised To See 600++ in next 12 to 18…
CYIENT 💚💚
NOW BLASTING
15%
NEW 52WK HIGH
584.85
379 TO 584.85 TILL NOW
NOW BLASTING
15%
NEW 52WK HIGH
584.85
379 TO 584.85 TILL NOW
Wealthcreatures.com
https://wealthcreatures.com/2020/03/30/mastek/ IF ONE CAN BEAR VOLATILITY START ADDING MASTEK ON ALL DIPS CMP - 1087 ADD ON DIPS TILL 1000/950 IN SIP 6 TO 12 MONTHS PATIENCE REQUIRED COMPANY DOING WELL UK & U.S BUSSINESS ARE ON TRACK CHEAPEST…
On RADAR
MASTEK
AGAIN
GOOD CONSOLIDATION HAPPENING BWT 1080 TO 1180 ZONE
EYES 👀 👁 ON 1205
EXPECTING upmove after Q3 NUMBERS AND ONCE CEO IS APPOINTED WE CAN EXPECT NEW 52WK HIGH
COMPANY IS PROCESS
MASTEK
AGAIN
GOOD CONSOLIDATION HAPPENING BWT 1080 TO 1180 ZONE
EYES 👀 👁 ON 1205
EXPECTING upmove after Q3 NUMBERS AND ONCE CEO IS APPOINTED WE CAN EXPECT NEW 52WK HIGH
COMPANY IS PROCESS
Wealthcreatures.com
LTTS Q3 FY21
LTTS
AS EXPEXTED GOING DOWN AFT RESULTS
2410/2385 SUPPORT LEVELS
LONGTERM SHOULD KEEP EYES ON THOSE LEVELS
BY Q4 EXPECTED AGAIN BACK ON TRACK
AS EXPEXTED GOING DOWN AFT RESULTS
2410/2385 SUPPORT LEVELS
LONGTERM SHOULD KEEP EYES ON THOSE LEVELS
BY Q4 EXPECTED AGAIN BACK ON TRACK
NIFTY SHOULD HOLD
14400 SUPPORT
14240 S/L FOR ALL LONG TRADES WHICH WAS RESPECTED LAST WEEK
14400 SUPPORT
14240 S/L FOR ALL LONG TRADES WHICH WAS RESPECTED LAST WEEK
Wealthcreatures.com
MEDIUM term PLAY VARROC ENGG CMP - 399 TEST LEVELS # 440/460/475++ Longterm # 525/600/750++ Support - 380 S/L - As per Risk
VARROC
UPMOVE
5% 💚💚
440 ✅
ALL LEVELS COMING SLOWLY
UPMOVE
5% 💚💚
440 ✅
ALL LEVELS COMING SLOWLY
Wealthcreatures.com
DEEPAK NITRITE ON RADAR EXPECTING UPMOVE VERY SOON CMP - 1020 One can Add light Qty here also bwt 990 to 1020 Support @ 976/960 Once closed above 1041 We can see New All Time High Expected Test levels # 1075/1111/1160++ S/L - As per Risk or 2%…
DEEPAK NITRITE
990 SUPPORT
CMP - 993
FUNDAMENTALLY STRONG STOCK
BUT NEED LOTS OF PATIENCE
990 SUPPORT
CMP - 993
FUNDAMENTALLY STRONG STOCK
BUT NEED LOTS OF PATIENCE
Wealthcreatures.com
MARKETS ARE AT HIGH NIFTY ALL TIME HIGH SENSEX ALL TIME HIGH ONE SHOULD PLAY VERY SAFE & TIME TO BE VERY CAUTIOUS NOW AS RISK REWARD IS NOT FAVOURABLE IN MARKETS BIG EVENT BUDGET IS COMING on 1st FEB'2021 BUDGET CAN BE SECTOR SPECIFIC & STOCK SPECIFIC…
GAVE UPDATE
WHEN NIFTY@14750
NOW - 14415
BANK NIFTY ALSO WHEN UPDATE GIVEN @ 32840
Now - 31150
HOPE this helped
TOLD TO BOOK PROFITS
NOW 2 SUPPORT ZONES
NIFTY @ 14400/14240
BAnk NIFTY @ 31000/30200
WHEN NIFTY@14750
NOW - 14415
BANK NIFTY ALSO WHEN UPDATE GIVEN @ 32840
Now - 31150
HOPE this helped
TOLD TO BOOK PROFITS
NOW 2 SUPPORT ZONES
NIFTY @ 14400/14240
BAnk NIFTY @ 31000/30200
Wealthcreatures.com
GAVE UPDATE WHEN NIFTY@14750 NOW - 14415 BANK NIFTY ALSO WHEN UPDATE GIVEN @ 32840 Now - 31150 HOPE this helped TOLD TO BOOK PROFITS NOW 2 SUPPORT ZONES NIFTY @ 14400/14240 BAnk NIFTY @ 31000/30200
14400 broken
Next Support Which was protected last Week 14240
Keep close eyes 👀 on that levels
Next Support Which was protected last Week 14240
Keep close eyes 👀 on that levels
Wealthcreatures.com
https://wealthcreatures.com/2019/07/26/mangalam-organic-time-to-slowly-accmulte-to-rip-benefits-in-long-term/ 💚MANGALAM ORGANIC 💚 8% up 120 TO 614 DONE 240 TO 475 STILL IN LONGTERM TRADE R.K DAMANI RECENTLY TOOK STAKE IN COMPANY PURE INVESTMENT PICK…
MANGALAM ORGANIC
YEST AGAIN UP 16%
Last Close - 555
High - 573
HAD UPDATE 2 DAYS BACK ALSO
Ready For new 52wk High
777/900++ coming
Just Need patience
YEST AGAIN UP 16%
Last Close - 555
High - 573
HAD UPDATE 2 DAYS BACK ALSO
Ready For new 52wk High
777/900++ coming
Just Need patience
Reliance Industries FY21Q3
Q3 Profit above expectation …ARPU beat expectation …Strong volume growth Chemical business
🎯Q3 Consolidated Net Profit Rs13011cr (up 12.6% YoY) – expectation Rs9300cr
🎯Jio net profit rises 15.5% (QoQ) to Rs 3,489 crore in Q3, revenue up 5.3 percent QoQ to Rs 19,475 crore.
🎯Average revenue per user (ARPU) of Rs 151 for the December quarter against Rs 145 – Expectation Rs149cr
🎯 Income Rs13729cr (up 18.6% YoY) – expectation Rs127800cr
🎯Chemicals business segment revenues for Q3FY21 increased by 10.0 percent QoQ to Rs 83,838 crore primarily on account of higher volumes
🎯 Reliance Retail Ventures revenue of Rs 37,845 crore in Q3 (down QoQ), EBITDA Rs3,087 crore(up 54%)
🎯Net profit for the quarter was Rs 1,830 crore, which was higher by 88.1 percent.
🎯 On O2C basis, total throughput has increased from 16.8 MMT to 18.2 MMT on QoQ basis due to improved product demand in Q3 and scheduled shutdown taken in Q2.
🎯 The increase in revenue was primarily due to higher price realizations and higher volumes in O2C segment, higher ARPU and FTTH expansion in Digital services business.
🎯 Outstanding debt as on 31st December, 2020 was Rs257,413 crore. Cash and cash equivalents as on 31 December, 2020 were at Rs220,524 crore.
Q3 Profit above expectation …ARPU beat expectation …Strong volume growth Chemical business
🎯Q3 Consolidated Net Profit Rs13011cr (up 12.6% YoY) – expectation Rs9300cr
🎯Jio net profit rises 15.5% (QoQ) to Rs 3,489 crore in Q3, revenue up 5.3 percent QoQ to Rs 19,475 crore.
🎯Average revenue per user (ARPU) of Rs 151 for the December quarter against Rs 145 – Expectation Rs149cr
🎯 Income Rs13729cr (up 18.6% YoY) – expectation Rs127800cr
🎯Chemicals business segment revenues for Q3FY21 increased by 10.0 percent QoQ to Rs 83,838 crore primarily on account of higher volumes
🎯 Reliance Retail Ventures revenue of Rs 37,845 crore in Q3 (down QoQ), EBITDA Rs3,087 crore(up 54%)
🎯Net profit for the quarter was Rs 1,830 crore, which was higher by 88.1 percent.
🎯 On O2C basis, total throughput has increased from 16.8 MMT to 18.2 MMT on QoQ basis due to improved product demand in Q3 and scheduled shutdown taken in Q2.
🎯 The increase in revenue was primarily due to higher price realizations and higher volumes in O2C segment, higher ARPU and FTTH expansion in Digital services business.
🎯 Outstanding debt as on 31st December, 2020 was Rs257,413 crore. Cash and cash equivalents as on 31 December, 2020 were at Rs220,524 crore.
https://wealthcreatures.com/2020/04/13/sbi-cards-only-listed-player-in-credit-available-33-below-ipo-price-value-buy-or-more-pain-coming/
SBI Cards and Payment Services
RESULTS UPDATE
The company has reported profit at Rs 209.65 crore in Q3FY21 against Rs 434.66 crore in Q3FY20, revenue fell to Rs 2,403.2 crore from Rs 2,479.1 crore YoY.
SBI Cards and Payment Services
RESULTS UPDATE
The company has reported profit at Rs 209.65 crore in Q3FY21 against Rs 434.66 crore in Q3FY20, revenue fell to Rs 2,403.2 crore from Rs 2,479.1 crore YoY.
WealthCreatures
SBI Cards – Only Listed Player in Credit – Available 34% Below IPO price – Value Buy or More pain Coming??
💢 SBI CARDS & PAYMENT SERVICES 💢 Cmp – 501 IPO PRICE – 755 MARKET CAP – 47400 crBOOK VALUE – 3952wk HIGH/LOW -769/5105 Year HIGH/LOW – N.AFACE VALUE – 10 DIV…
Wealthcreatures.com
ONE PORTFOLIO PHARMA PICK GLAND PHARMA CMP - 2175 ACCMULATE # 2050 TO 2175 SUPPORT@ 1990 EXPECTING 50% TO 100% RETURNS IN NEXT 12 TO 24 MONTHS S/L - 1780 on cbsl or as per Risk. Disc - Study before investing. All views expressed are personal and…
Gland Pharma
Q3FY21 UPDATE
Net profit rises 32% to ₹204 crore
Gland Pharma Limited has posted robust results for the third quarter and nine months ended December 31, 2020 with the company logging a profit of ₹204 crore up 32 per cent over ₹154 crore it posted for the corresponding third quarter last year.
The pharma company posted revenues of ₹859.4 crore for the third quarter up 33 per cent over ₹645.9 crore for the corresponding quarter last fiscal.
For the nine months ended December 31, the company had a profit of ₹736.6 crore, up 27 per cent over ₹578 crore of same period last year.
The revenue for nine months was up 27 per cent at ₹2,575 crore as against ₹1,998 crore for same period of previous fiscal.
Srinivas Sadu, MD & CEO of Gland Pharma, said: “Our growth momentum has continued in the third quarter and we reported revenue growth of 33 per cent and net profit growth of 32 per cent over the corresponding quarter of the previous year.
The business growth drivers were new product launches, geographic expansion of business and volume growth in existing portfolio, which is in line with our strategy.”
During the nine months ended December 31, 2020, the company has filed 19 ANDAs, 5 DMFs and received 24 ANDA approvals.
As on December, the company has filed 282 ANDAs, out of which 226 were approved and 56 are pending approval. The company has launched 41 products comprising 23 molecules during the period.
Capital expenditure
The company incurred a total capex of ₹182.6 crore during the nine months ended December 31, 2020. The company is expanding its sterile injectable facility located in Hyderabad and is enhancing its production capacity for both APIs and finished formulations.
Q3FY21 UPDATE
Net profit rises 32% to ₹204 crore
Gland Pharma Limited has posted robust results for the third quarter and nine months ended December 31, 2020 with the company logging a profit of ₹204 crore up 32 per cent over ₹154 crore it posted for the corresponding third quarter last year.
The pharma company posted revenues of ₹859.4 crore for the third quarter up 33 per cent over ₹645.9 crore for the corresponding quarter last fiscal.
For the nine months ended December 31, the company had a profit of ₹736.6 crore, up 27 per cent over ₹578 crore of same period last year.
The revenue for nine months was up 27 per cent at ₹2,575 crore as against ₹1,998 crore for same period of previous fiscal.
Srinivas Sadu, MD & CEO of Gland Pharma, said: “Our growth momentum has continued in the third quarter and we reported revenue growth of 33 per cent and net profit growth of 32 per cent over the corresponding quarter of the previous year.
The business growth drivers were new product launches, geographic expansion of business and volume growth in existing portfolio, which is in line with our strategy.”
During the nine months ended December 31, 2020, the company has filed 19 ANDAs, 5 DMFs and received 24 ANDA approvals.
As on December, the company has filed 282 ANDAs, out of which 226 were approved and 56 are pending approval. The company has launched 41 products comprising 23 molecules during the period.
Capital expenditure
The company incurred a total capex of ₹182.6 crore during the nine months ended December 31, 2020. The company is expanding its sterile injectable facility located in Hyderabad and is enhancing its production capacity for both APIs and finished formulations.
Wealthcreatures.com
#InvestmentPick KNR Construction Accumualte :290-310 SL 270 T : 450+ Note : Add 60% Quantity here and Rest 40% When Positiin Goes in Profit above 350
KNR ON RADAR
KNR CONSTRUCTION
Company fixes Bonus Issue (1:1) Record date on 4 Feb 2021 .
Also Approves Increases in authorised share capital from Rs 35 Cr to 60 cr .
KNR CONSTRUCTION
Company fixes Bonus Issue (1:1) Record date on 4 Feb 2021 .
Also Approves Increases in authorised share capital from Rs 35 Cr to 60 cr .
UltraTech Cement
Good numbers
Cmp - 5540
Test levels # 5800/6000/6300++
The company reported higher consolidated profit at Rs 1,584 crore in Q3FY21 against Rs 711 crore, revenue jumped to Rs 12,254.1 crore from Rs 10,439.3 crore YoY.
Good numbers
Cmp - 5540
Test levels # 5800/6000/6300++
The company reported higher consolidated profit at Rs 1,584 crore in Q3FY21 against Rs 711 crore, revenue jumped to Rs 12,254.1 crore from Rs 10,439.3 crore YoY.
RESULTS TODAY OF OUR PICKS
ASTEC LIFESCIENCES
AARTI DRUGS
CHENNAI PETRO
NAVIN FLOURIDE
ASTEC LIFESCIENCES
AARTI DRUGS
CHENNAI PETRO
NAVIN FLOURIDE
Wealthcreatures.com
DONT MISS POLYCAB STILL ONE CAN ADD BWT - 940 To 960 zone ONCE CLOSED AVOVE 977 CAN SEE BIH UPMOVE 990/1040/1075/1111+++ LONGTERM - 1400/1600++
POLYCAB INDIA
Q3 FY21
The company reported lower consolidated profit at Rs 262.5 crore in Q3FY21 against Rs 600.6 crore in Q3FY20, revenue fell to Rs 2,798.8 crore from Rs 5,889.1 crore YoY.
Q3 FY21
The company reported lower consolidated profit at Rs 262.5 crore in Q3FY21 against Rs 600.6 crore in Q3FY20, revenue fell to Rs 2,798.8 crore from Rs 5,889.1 crore YoY.